A single intravitreal injection improved acuity in Stargardt disease; a randomized trial in geographic atrophy is planned. A single intravitreal injection improved acuity in Stargardt disease; a randomized trial in geographic atrophy is planned. ... age-related macular degeneration (AMD) slow lesion growth but do not recover lost vision. Data presented at the 130th Annual Meeting of the American Academy of Ophthalmology (AAO) in New Orleans from October 9-12, 2026, suggest that an optogenetic gene therapy may eventually address that gap.1 The human data so far come from small, open-label cohorts with an inherited disease, not from older adults with AMD. Boyer said he had expected that the therapy's effect on remaining viable cells might obscure any acuity benefit, and that this did not happen.1 Whether that holds in eyes with GA—which typically retain more functioning photoreceptors at the lesion margins—is still unknown. Neither has been shown to improve visual acuity.5,6 And no approved therapy currently restores function to the retina, where photoreceptors have already been lost. Rather than using gene replacement, son-vec uses optogenetics. Through this treatment approach, an adeno-associated viral vector delivers a gene encoding a multi-characteristic opsin to ON bipolar cells, which often survive after photoreceptors degenerate; and the bipolar cells then respond directly to light.1,7 Because this approach does not target a specific causative mutation, it is described as mutation agnostic. The presentation highlights 2 lines of research.1 The first: an open-label, multicenter phase 2 study in which patients with Stargardt disease and visual acuity of 20/200 or worse each received a single injection of son-vec. According to the data, patients whose atrophy was limited to the macula gained an average of 12 Early Treatment Diabetic Retinopathy Study (ETDRS) letters. The therapy was well tolerated, with no serious adverse events (AEs) reported.1

BERKELEY, Calif.--(BUSINESS WIRE)--Ray ... therapies for those living with severe retinal degenerations, today announced it has been awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to advance RTx-021 for the treatment of Stargardt disease. The funding will support the ongoing Phase 1/2 clinical trial and manufacturing ... BERKELEY, Calif.--(BUSINESS WIRE)--Ray Therapeutics (RayTx), an industry-leading clinical-stage biopharmaceutical company pioneering differentiated vision restoration therapies for those living with severe retinal degenerations, today announced it has been awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to advance RTx-021 for the treatment of Stargardt disease. The funding will support the ongoing Phase 1/2 clinical trial and manufacturing activities to prepare the program for late-stage development. Stargardt disease is the most common form of juvenile macular degeneration, and about 40,000 people in the United States are living with the condition. It is caused by mutations that lead to photoreceptor loss over time, resulting in progressive loss of central vision. ... RayTx is a clinical-stage biopharmaceutical company advancing optogenetic gene therapies to restore vision in people with retinal degenerative diseases. The California Institute for Regenerative Medicine (CIRM) is a state agency created by California voters to accelerate stem cell and gene therapies for people with unmet medical needs. Since 2004, Californians have entrusted CIRM with $8.5 billion to accelerate promising discoveries through clinical trials, train a regenerative medicine workforce, strengthen the state’s biotechnology economy, and expand access to transformative therapies. It is clear that Stargardt’s patients need life-changing treatments that can help them maintain their independence and navigate daily life with confidence,” said Paul Webb, PhD, Senior Science Officer for Clinical Development of CIRM. “CIRM’s mission is to help bring promising science to the patients who need it. We’re hopeful that this approach will advance a potential vision-restoring therapy for people in California and around the world who currently have no approved treatment options.”

Tarsus Pharmaceuticals has acquired Alkeus for up to $800 million, gaining access to a promising therapy for Stargardt disease currently in late-stage testing. This acquisition highlights the potential value of innovative treatments in the rare eye disease space.

Stargardt Disease. American Academy of Ophthalmology. Macula. American Academy of Ophthalmology. Vision Loss, Central. MedlinePlus. Stargardt macular degeneration. National Cancer Institute. Choroid. MedlinePlus. Choroideremia. National Organization of Rare Disorders. Choroideremia. U.S. Food & Drug Administration. FDA approves novel gene therapy to treat patients with a rare form of inherited ... Stargardt Disease. American Academy of Ophthalmology. Macula. American Academy of Ophthalmology. Vision Loss, Central. MedlinePlus. Stargardt macular degeneration. National Cancer Institute. Choroid. MedlinePlus. Choroideremia. National Organization of Rare Disorders. Choroideremia. U.S. Food & Drug Administration. FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss. This gene is associated with several IRDs, including retinitis pigmentosa. Other therapies in development include medications that prevent the death of cells in the eyes and prosthetics that are implanted into the eye to restore vision. Sources: PreventBlindness.org. Eye Diseases & Con... + 13 · PreventBlindness.org. Eye Diseases & Conditions: Inherited Retinal Diseases. Why family medical history matters to the health of your eyes.How your genetics can affect your vision ... Get a look at the healthcare providers you may work with if you are living with an inherited retinal disease (IRD).The specialists and therapies that treat IRDs Keep in mind that this is a simplified explanation of this condition—there are more than 60 different genes that can be involved in the development of RP, there are numerous subtypes of RP, the disease can follow different patterns, and it can occur as a result of multiple other genetic disorders. It’s estimated that RP affects one out of every 3,000 or 4,000 people. This inherited retinal disease is the most common form of juvenile macular degeneration and symptoms typically begin in late childhood or young adulthood.

City has secured nearly $100 million to advance its next-generation RNAi drugs, including a clotting disorder treatment currently in early human testing. An experimental therapy for Stargardt disease is also on the horizon.